Sana Biotechnology, Inc. Operating Lease, Liability, Current
Sana Biotechnology, Inc. (SANA) had Operating Lease, Liability, Current of $14.51 million as of 2026-06-30, per its 10-Q filed 2026-08-10.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseLiabilityCurrent · last filed 2026-08-10
- 2026-06-30: Operating Lease, Liability, Current $14.51M.
- 2026-03-31: Operating Lease, Liability, Current $14.88M.
- 2025-12-31: Operating Lease, Liability, Current $14.94M.
- 2025-09-30: Operating Lease, Liability, Current $14.37M.
| Period end | Operating Lease, Liability, Current |
|---|---|
| 2026-06-30 | $14.51M 10-Q · filed 2026-08-10 |
| 2026-03-31 | $14.88M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $14.94M 10-Q · filed 2026-08-10 |
| 2025-09-30 | $14.37M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $13.83M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $13.00M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $12.53M 10-K · filed 2026-03-03 |
| 2024-09-30 | $10.60M 10-Q · filed 2024-11-08 |
| 2024-06-30 | $10.00M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $13.17M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $13.20M 10-K · filed 2025-03-17 |
| 2023-09-30 | $13.49M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $12.89M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $12.89M 10-Q · filed 2023-05-08 |
| 2022-12-31 | $12.39M 10-K · filed 2024-02-29 |
| 2022-09-30 | $11.92M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $10.67M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $9.63M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $9.16M 10-K · filed 2023-03-16 |
| 2021-09-30 | $6.50M 10-Q · filed 2021-11-08 |
| 2021-06-30 | $6.00M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $3.91M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $3.71M 10-K · filed 2022-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |